NCT03912207View on ClinicalTrials.gov

Investigating Immune Responses to Aerosol BCG Challenge in Healthy UK Adults

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

April 19, 2019

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions
Tuberculosis
Interventions
BIOLOGICAL

BCG Danish

BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.

OTHER

Saline placebo

Saline is a routinely used placebo.

Trial Locations (2)

OX3 7LE

Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Churchill Hospital, Oxford

Oxford University Hospitals- John Warin Ward, University of Oxford, Oxford

All Listed Sponsors
collaborator

Wellcome Trust

OTHER

collaborator

National Institute for Health Research, United Kingdom

OTHER_GOV

collaborator

University of Leicester

OTHER

lead

University of Oxford

OTHER

NCT03912207 - Investigating Immune Responses to Aerosol BCG Challenge in Healthy UK Adults | Biotech Hunter | Biotech Hunter